tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Karl Chalabala, 8 are a BUY (88.89%), 1 are a HOLD (11.11%).
Analyst Karl Chalabala, currently employed at UBS, carries an average stock price target met ratio of 25% that have a potential upside of 10.99% achieved within 453 days. Previously, Karl Chalabala worked at STIFEL.
Karl Chalabala’s has documented 14 price targets and ratings displayed on 4 stocks. The coverage is on Energy, Healthcare sectors.
Most recent stock forecast was given on FOLD, Amicus Therapeutics at 10-May-2024.
Analyst best performing recommendations are on EQT (EQT).
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy
$65
$10.94 (20.24%)
$64
1 months 18 days ago
(20-Aug-2025)
9/11 (81.82%)
$13.66 (26.61%)
140
Buy
$70
$15.94 (29.49%)
$55
3 months ago
(08-Jul-2025)
6/7 (85.71%)
$15.14 (27.60%)
386
Buy
$60
$5.94 (10.99%)
$51
6 months 21 days ago
(17-Mar-2025)
5/5 (100%)
$8.34 (16.14%)
267
Buy
$66
$11.94 (22.09%)
$43
7 months 26 days ago
(12-Feb-2025)
1/2 (50%)
$13.63 (26.03%)
223
Hold
$55
8 months 22 days ago
(16-Jan-2025)
2/2 (100%)
$18.47 (50.56%)
642
What Year was the first public recommendation made by Karl Chalabala?
